Atlas Trials

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Clinical trial NCT04427072 · TERMINATED

Trial details

NCT number
NCT04427072
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell Lung
Start date
2020-09-25
Primary completion
2023-02-15
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.